UXCONTRACTNETWORK

UX Contract › Grants › PAR-25-226

ACCEPTING APPLICATIONS · COOPERATIVE AGREEMENT

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health · Health

Accepting applications. The agency is taking applications now through Grants.gov.
Deadline
Nov 19, 2026 (26 days left)
Who can apply
Others
Award range
Not stated
Expected awards
Not stated
Total program funding
Not stated
Your own money required
No cost sharing or matching required
Opportunity number
PAR-25-226
Posted
Nov 22, 2024
Assistance listing
93.242

More on who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Pos

What it funds

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

Open the official notice on Grants.gov ↗

What to do next

  1. Open the official notice on Grants.gov and download the full announcement (the NOFO) and any attachments.
  2. Check you can apply: the eligible applicants above, and any detail in the notice's eligibility section.
  3. Register your organization in SAM.gov (choose "all awards") and create a Grants.gov account; allow several weeks the first time.
  4. Apply through Grants.gov exactly as the notice says, before Nov 19, 2026. Late applications are usually not accepted.

New to this? Applying for a federal grant, step by step · Register to apply · How to read the notice · Write the narrative · Build the budget · Agency contact: grantsinfo@nih.gov

From Grants.gov's official daily extract of Oct 25, 2026. The notice on Grants.gov and its attachments are what count. UX Contract is independent and not a government website.

Just listed by agency

Live feed →

More health grants accepting applications

Track the auctions and bids you're watching in UX Console

See plans →

Saved searches, closing and deadline alerts, and your won auctions with the real costs, in one workspace. From $10 a month. Every site in the UX Network stays free.